The 76-week trial met its co-primary endpoints, with up to 13.1% average weight loss using the efficacy estimand and improvements in HbA1c, waist circumference and insulin sensitivity. IN BRIEFKEY TAKEAWAYSFAQs Boehringer Ingelheim reported positive Phase III SYNCHRONIZE-2 results for investigational … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged BI 456906, Boehringer Ingelheim, Boehringer Ingelheim presents survodutide Phase III results in obesity or overweight with type 2 diabetes, Boehringer Ingelheim’s SYNCHRONIZE-2 trial reports up to 13.1% average weight loss with investigational survodutide in adults with type 2 diabetes, cardiometabolic health, Dual Agonist, EASD, European Association for the Study of Diabetes, Germany, GLP-1, glucagon receptor, glycemic control, HbA1c, Ingelheim, insulin sensitivity, LIVERAGE, LIVERAGE-Cirrhosis, MASH, Obesity, overweight, Phase III SYNCHRONIZE-2 data show survodutide met co-primary weight-loss endpoints and improved glycemic markers, Sean Wharton, Shashank Deshpande, Survodutide, SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-2 findings show weight reduction alongside HbA1c and insulin-sensitivity improvements with survodutide, SYNCHRONIZE-CVOT, SYNCHRONIZE-T2D, T2D, The New England Journal of Medicine, type 2 diabetes, Zealand Pharma
(IN BRIEF) In a significant stride towards combating metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim unveils groundbreaking results from a Phase II trial sub-analysis of survodutide. Demonstrating impressive efficacy, up to 64.5% of adults with moderate to advanced fibrosis stages F2 … Read the full press release
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the glucagon/GLP-1 receptors, into three Phase III clinical trials for individuals suffering from overweight or obesity. This decision stems from promising … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?